The spectrum of tuberculosis infection: New perspectives in the era of biologics

Journal of Rheumatology

Volumn 41, Issue SUPPL. 91, 2014, Pages 11-16

  Delogu, Giovanni ^a   Goletti, Delia ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b Lazzaro Spallanzani   (Italy)

Author keywords

Biologic therapies; Latent infection; Tuberculosis

Indexed keywords

BACTERIAL PROTEIN; BIOLOGICAL PRODUCT; CORTICOSTEROID; INFLIXIMAB; RESUSCITATION PROMOTING FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ADAPTIVE IMMUNITY; ANAEROBIC METABOLISM; ARTICLE; BACTERIAL GROWTH; BACTERIAL PHENOMENA AND FUNCTIONS; BACTERIAL REACTIVATION; BACTERIUM REPLICATION; BIOLOGICAL THERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; LATENT PERIOD; LATENT TUBERCULOSIS; LUNG ALVEOLUS MACROPHAGE; LUNG GRANULOMA; LYMPHOCYTE FUNCTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; RISK;

BIOLOGICAL PRODUCTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOBACTERIUM TUBERCULOSIS; RISK; TUBERCULOSIS;

EID: 84899797129     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140097     Document Type: Article

References (52)

1. Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 2011;4:288-93
2. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 2008;205:105-15 (Pubitemid 351185719)
3. Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, Fountain JJ, et al. ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci U S A 2008;105:10961-6
4. Gallegos AM, Pamer EG, Glickman MS. Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J Exp Med 2008;205:2359-68
5. Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol 2007;5:39-47 (Pubitemid 44942302)
6. Russell DG, Barry CE III, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science 2010;328:852-6
7. Bishai WR. Rekindling old controversy on elusive lair of latent tuberculosis. Lancet 2000;356:2113-4 (Pubitemid 32047941)
8. Ghon N. The primary complex in human tuberculosis and its significance. Am Rev Tuberc 1923;7:314-7
9. Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, Harboe M, et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000;356:2133-8
10. Neyrolles O, Hernandez-Pando R, Pietri-Rouxel F, Fornes P, Tailleux L, Barrios Payan JA, et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS ONE 2006;1:e43
11. Gengenbacher M, Kaufmann SH. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 2012;36:514-32
12. Kaufmann SH, Gengenbacher M. Recombinant live vaccine candidates against tuberculosis. Curr Opin Biotechnol 2012; 23:900-7
13. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM, et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 2009;10:899-906
14. Balasubramanian V, Wiegeshaus EH, Taylor BT, Smith DW. Pathogenesis of tuberculosis: pathway to apical localization. Tuber Lung Dis 1994;75:168-78 (Pubitemid 24217271)
15. Delogu G, Sanguinetti M, Posteraro B, Rocca S, Zanetti S, Fadda G. The hbhA gene of Mycobacterium tuberculosis is specifically upregulated in the lungs but not in the spleens of aerogenically infected mice. Infect Immun 2006;74:3006-11 (Pubitemid 43673012)
16. Menozzi FD, Reddy VM, Cayet D, Raze D, Debrie AS, Dehouck MP, et al. Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. Microbes Infect 2006;8:1-9 (Pubitemid 43139286)
17. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, Locht C, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001;412:190-4 (Pubitemid 32674716)
18. Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol 2010;64:293-311
19. Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res 2011;50:202-12
20. Kumar A, Toledo JC, Patel RP, Lancaster JR Jr., Steyn AJ. Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia sensor. Proc Natl Acad Sci U S A 2007;104:11568-73 (Pubitemid 47175053)
21. Daniel J, Deb C, Dubey VS, Sirakova TD, Abomoelak B, Morbidoni HR, et al. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J Bacteriol 2004;186:5017-30 (Pubitemid 38970829)
22. Voskuil MI, Visconti KC, Schoolnik GK. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis 2004;84:218-27 (Pubitemid 38857854)
23. Korch SB, Contreras H, Clark-Curtiss JE. Three Mycobacterium tuberculosis Rel toxin-antitoxin modules inhibit mycobacterial growth and are expressed in infected human macrophages. J Bacteriol 2009;191:1618-30
24. Hett EC, Chao MC, Rubin EJ. Interaction and modulation of two antagonistic cell wall enzymes of mycobacteria. PLoS Pathog 2010;6:e1001020
25. Kana BD, Gordhan BG, Downing KJ, Sung N, Vostroktunova G, Machowski EE, et al. The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol 2008;67:672-84
26. Mukamolova GV, Turapov O, Malkin J, Woltmann G, Barer MR. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010;181:174-80
27. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3 Suppl 2:S231-79 (Pubitemid 29481843)
28. Klinkenberg LG, Sutherland LA, Bishai WR, Karakousis PC. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 2008;198:275-83 (Pubitemid 352019294)
29. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:2054-8 (Pubitemid 24278800)
30. Zhang Y. Metronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosis. Proc Natl Acad Sci U S A 2012;109:13890-1
31. Tarshis MS, Weed WA Jr. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 1953;67:391-5
32. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE III, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011;333:1630-2
33. Barry CE, III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7:845-55
34. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000;216:117-21 (Pubitemid 30434730)
35. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect Immun 2009;77:4631-42
36. Ford CB, Lin PL, Chase MR, Shah RR, Iartchouk O, Galagan J, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011;43:482-6
37. Sherman DR, Gagneux S. Estimating the mutation rate of Mycobacterium tuberculosis during infection. Nat Genet 2011;43:400-1
38. Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection 2009;37:80-6
39. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009;17:183-8
40. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009;13:84-92
41. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174:831-9 (Pubitemid 44511666)
42. Corbiere V, Pottier G, Bonkain F, Schepers K, Verscheure V, Lecher S, et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS One 2012;7:e43285
43. Achkar JM, Casadevall A. Antibody-mediated immunity against Microbe 2013;13:250-62
44. Donald PR, Marais BJ, Barry CE III. Age and the epidemiology and pathogenesis of tuberculosis. Lancet 2010;375:1852-4
45. Wallis RS. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis 2009;22:403-9
46. Lin PL, Myers A, Smith L, Bigbee C, Bigbee M, Fuhrman C, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010;62:340-50
47. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72
48. Miller EA, Ernst JD. Illuminating the black box of TNF action in tuberculous granulomas. Immunity 2008;29:175-7
49. Beham AW, Puellmann K, Laird R, Fuchs T, Streich R, Breysach C, et al. A TNF-regulated recombinatorial macrophage immune receptor implicated in granuloma formation in tuberculosis. PLoS Pathog 2011;7:e1002375
50. Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, Modlin RL, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009;119:1167-77
51. Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest 2009;119:1079-82
52. Kaufmann SH, Cole ST, Mizrahi V, Rubin E, Nathan C. Mycobacterium tuberculosis and the host response. J Exp Med 2005;201:1693-7 (Pubitemid 41002887)